Multicentre controlled open randomised clinical trial to assess efficacy and safety of an anti-tuberculosis drug combination based on optimised-dose rifampicin, optimised-dose moxifloxacin and optimised-dose linezolid for TB: the RML-TB trial protoco
Authors
Xavier Clop i García (ORCID: https://orcid.org/0000-0002-1875-5554)
Multicentre controlled open randomised clinical trial to assess efficacy and safety of an anti-tuberculosis drug combination based on optimised-dose rifampicin, optimised-dose moxifloxacin and optimised-dose linezolid for TB: the RML-TB trial protoco
Xavier Clop i García, Virginia Pomar Solchaga, Rafael Luque Márquez, Joan-Pau Millet et al.
Journal
BMJ Open Respiratory Research
Topics
Tuberculosis Research and Epidemiology
article
Multicentre controlled open randomised clinical trial to assess efficacy and safety of an anti-tuberculosis drug combination based on optimised-dose rifampicin, optimised-dose moxifloxacin and optimised-dose linezolid for TB: the RML-TB trial protoco
Xavier Clop i García, Virginia Pomar Solchaga, Rafael Luque Márquez, Joan-Pau Millet, Tamar Talaván Zanón, Verónica González Galán, María Francisca Portero, Núria Saborit, Ramón Rabuñal Rey, Jesús Troya, Raymond Serrano, Juan Espinosa Pereiro, Francisco Sanz, Marcos Díez, María Luisa Aznar, Adrián Sánchez‐Montalvá, Ana Gil-Brusola, Marta Montero, Juan Francisco Medina Gallardo, Luis Anibarro, Pilar Alonso García, Pedro Antonio García López, Joan Martínez Campreciós, Enrique Navas, Alberto Díaz de Santiago, María Teresa Tórtola Fernández, Laura Diab Casares, Montserrat Garrigó Fullola
article en
Abstract
No abstract available for this paper.
Publication Tag
BMJ Open Respiratory ResearchVol. 12(1)
Institutions
Universitat Autònoma de Barcelona (ES), Universitat de València (ES), Instituto de Salud Carlos III (ES), Hospital de Sant Pau (ES), Hospital Universitari i Politècnic La Fe (ES), Hospital Universitario Puerta de Hierro Majadahonda (ES), Sociedad Española de Medicina de Familia y Comunitaria (ES), Centre for Biomedical Network Research on Rare Diseases (ES), Hospital Clínic de Barcelona (ES), Public Health Agency (GB), Catalan Society of Family and Community Medicine (ES), Vall d'Hebron Hospital Universitari (ES), Hospital General Universitario De Valencia (ES), Instituto de Biomedicina de Sevilla (ES), Biomedical Research Institute (US), Spanish Society of Hematology and Hemotherapy (ES), Hospital Universitario Lucus Augusti (ES), Instituto de Investigación Sanitaria de Santiago (ES), Hospital Universitario Virgen del Rocío (ES), Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES), Complejo Hospitalario de Pontevedra (ES), Hospital Universitario Ramón y Cajal (ES), Biomedal (Spain) (ES), Hospital Universitario Infanta Leonor (ES)